Yasuyuki Aotsuka

Title: Yasuyuki Aotsuka: Innovator in Anti-Cancer Antibodies

Introduction

Yasuyuki Aotsuka is a notable inventor based in Kobe, Japan. He has made significant contributions to the field of medical and pharmaceutical research, particularly in the development of anti-cancer antibodies. His work focuses on the amino acid sequences of anti-idiotypic antibodies, which play a crucial role in the treatment and diagnosis of human diseases.

Latest Patents

Aotsuka holds a patent for "Amino acid sequences of anti-idiotypic antibodies against anti-cancer." This patent includes the amino acid sequences of the H chain and L chain variable regions of mouse monoclonal antibodies Idio 3, Idio 17, Idio 20, Idio 27, and Idio 33. These antibodies are designed to target idiotypes of a cancer cell antigen-specific human immunoglobulin CLN/IgG, produced by a human/human fused cell strain CLN/SUZ H11. The disclosed amino acid sequences and base sequences of the genes of the variable regions are valuable in various medical and pharmaceutical applications, including prophylaxis, treatment, and diagnosis of human diseases.

Career Highlights

Aotsuka's career is marked by his dedication to advancing medical science through innovative research. His work has led to the development of important biochemical reagents and purification methods for biomacromolecules. He is associated with the company Yoshihide Hagiwara, where he continues to contribute to groundbreaking research.

Collaborations

Aotsuka collaborates with Hideaki Hagiwara, enhancing the impact of their research in the field of anti-cancer therapies. Their partnership exemplifies the importance of teamwork in scientific innovation.

Conclusion

Yasuyuki Aotsuka is a prominent figure in the realm of anti-cancer research, with a patent that showcases his innovative approach to medical science. His contributions are vital for the development of new treatments and diagnostic tools for human diseases.